SNORA77: A Potential Drug Target and Biomarker (G677843)

Target Name: SNORA77

NCBI ID: G677843

SNORA77

Other Name(s): Small nucleolar RNA, H/ACA box 77 | ACA63 | SNORA77A | small nucleolar RNA, H/ACA box 77

SNORA77: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA), also known as H/ACA box 77, is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in the nucleus. It is composed of 199 nucleotides and has a typical length of approximately 20-30 nucleotides. SNORA77 is located in the H/ACA box 77 region of the human nuclear genome, which is a known hot spot for the expression of snRNAs.

The H/ACA box is a conserved region that is present in various organisms, including humans. It is named after the H/ACA protein, which is a component of the nucleolus and is involved in the processing and stability of rRNA. /ACA box is a critical region for the regulation of gene expression, as it contains elements that are involved in the binding of transcription factors to their target genes.

SNORA77 is a well-characterized snRNA that has been shown to play a role in the regulation of gene expression in various organisms, including humans. It is expressed in a variety of tissues and cells, including the brain, heart, and pancreas, and has has been shown to be involved in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation.

One of the key functions of SNORA77 is its role in the regulation of gene expression. It is well-established that SNORA77 interacts with various transcription factors, including histone-modifying RNA-binding protein (RBP), promoter enhancer (PES), and DNA-binding proteins (TBP) bound by transcription factors. Through these interactions, SNORA77 can regulate the expression level of target genes, thereby affecting biological processes such as cell cycle, apoptosis, and inflammation.

In addition, SNORA77 also has other biological functions. For example, it can bind to DNA and participate in the composition of DNA-binding protein (DBP); at the same time, it can also bind to RNA and may participate in the composition of RNA-binding protein (RBP). These functions make SNORA77 a potential drug target.

In recent years, researchers have studied SNORA77 more and more. Many studies have shown that SNORA77 can inhibit the expression of target genes by inhibiting its binding protein, thereby having pharmacological activity. For example, some studies have found that SNORA77 can inhibit the inhibitory effect of the anti-apoptotic drug doxorubicin (Amdmycin) on the apoptosis inducer Bcl-2. In addition, SNORA77 can also inhibit cell proliferation, thus having anti-cancer effects.

In addition, some studies have also shown that SNORA77 is closely related to the occurrence and development of some diseases. For example, some studies have found that the expression level of SNORA77 can be used to predict the survival rate of patients with pancreatic cancer. In addition, SNORA77 is also related to neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, etc.

In summary, SNORA77 is a molecule worthy of attention. By inhibiting its binding protein, SNORA77 can produce pharmacological activities and participate in a variety of biological processes. Therefore, SNORA77 is a potential drug target and has broad application prospects.

Protein Name: Small Nucleolar RNA, H/ACA Box 77

The "SNORA77 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA77 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets